Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations

Journal of Experimental Medicine

Volumn 203, Issue 2, 2006, Pages 371-381

  Radomska, Hanna S ^a   Bassères, Daniela S ^a   Zheng, Rui ^c   Zhang, Pu ^a   Dayaram, Tajhal ^a   Yamamoto, Yukiya ^a   Sternberg, David W ^b   Lokker, Nathalie ^d   Giese, Neill A ^d   Bohlander, Stefan K ^e   Schnittger, Susanne ^e   Delmotte, Marie Hélène ^f   Davis, Roger J ^f   Small, Donald ^b   Hiddemann, Wolfgang ^e   Gilliland, D Gary ^b   Tenen, Daniel G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; ALANINE; ASPARTIC ACID; CCAAT ENHANCER BINDING PROTEIN ALPHA; FLT3 LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SERINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CASE REPORT; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GRANULOCYTE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

AGED; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL DIFFERENTIATION; CELL LINE; ENZYME ACTIVATION; FEMALE; FMS-LIKE TYROSINE KINASE 3; GRANULOCYTES; HUMANS; K562 CELLS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MAP KINASE KINASE 1; MYELOID CELLS; PHOSPHORYLATION; PIPERAZINES; POINT MUTATION; QUINAZOLINES; SERINE; TUMOR CELLS, CULTURED; U937 CELLS;

EID: 33344455424     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20052242     Document Type: Article

References (70)

1. Tenen, D.G. 2003. Disruption of differentiation in human cancer: AML shows the way. Nat. Rev. Cancer. 3:89-101.
2. Mrozek, K., K. Heinonen, and C.D. Bloomfield. 2001. Clinical importance of cytogenetics in acute myeloid leukaemia. Best. Pract. Res. Clin. Haematol. 14:19-47.
3. Gilliland, D.G., and J.D. Griffin. 2002. The roles of FLT3 in hematopoiesis and leukemia. Blood. 100:1532-1542.
4. Nakao, M., S. Yokota, T. Iwai, H. Kaneko, S. Horiike, K. Kashima, Y. Sonoda, T. Fujimoto, and S. Misawa. 1996. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 10:1911-1918.
5. Brown, P., and D. Small. 2004. FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. Eur. J. Cancer. 40:707-721.
6. Yamamoto, Y., H. Kiyoi, Y. Nakano, R. Suzuki, Y. Kodera, S. Miyawaki, N. Asou, K. Kuriyama, F. Yagasaki, C. Shimazaki, et al. 2001. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 97:2434-2439.
7. Abu-Duhier, F.M., A.C. Goodeve, G.A. Wilson, R.S. Care, I.R. Peake, and J.T. Reilly. 2001. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br. J. Haematol. 113:983-988.
8. Tse, K.F., G. Mukherjee, and D. Small. 2000. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia. 14:1766-1776.
9. Hayakawa, F., M. Towatari, H. Kiyoi, M. Tanimoto, T. Kitamura, H. Saito, and T. Naoe. 2000. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 19:624-631.
10. Mizuki, M., R. Fenski, H. Halfter, I. Matsumura, R. Schmidt, C. Muller, W. Gruning, K. Kratz-Albers, S. Serve, C. Steur, et al. 2000. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 96:3907-3914.
11. Spiekermann, K., K. Bagrintseva, R. Schwab, K. Schmieja, and W. Hiddemann. 2003. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin. Cancer Res. 9:2140-2150.
12. Rosnet, O., H.J. Buhring, S. Marchetto, I. Rappold, C. Lavagna, D. Sainty, C. Arnoulet, C. Chabannon, L. Kanz, C. Hannum, and D. Birnbaum. 1996. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia. 10:238-248.
13. Rasko, J.E., D. Metcalf, M.T. Rossner, C.G. Begley, and N.A. Nicola. 1995. The flt3/flk-2 ligand: receptor distribution and action on murine haemopoietic cell survival and proliferation. Leukemia. 9:2058-2066.
14. Abu-Duhier, F.M., A.C. Goodeve, G.A. Wilson, M.A. Gari, I.R. Peake, D.C. Rees, E.A. Vandenberghe, P.R. Winship, and J.T. Reilly. 2000. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br. J. Haematol. 111:190-195.
15. Kiyoi, H., T. Naoe, Y. Nakano, S. Yokota, S. Minami, S. Miyawaki, N. Asou, K. Kuriyama, I. Jinnai, C. Shimazaki, et al. 1999. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 93:3074-3080.
16. Kottaridis, P.D., R.E. Gale, M.E. Frew, G. Harrison, S.E. Langabeer, A.A. Belton, H. Walker, K. Wheatley, D.T. Bowen, A.K. Burnett, et al. 2001. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the UK Medical Research Council AML 10 and 12 trials. Blood. 98:1752-1759.
17. Rombouts, W.J., I. Blokland, B. Lowenberg, and R.E. Ploemacher. 2000. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia. 14:675-683.
18. Whitman, S.P., K.J. Archer, L. Feng, C. Baldus, B. Becknell, B.D. Carlson, A.J. Carroll, K. Mrozek, J.W. Vardiman, S.L. George, et al. 2001. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 61:7233-7239.
19. Frohling, S., R.F. Schlenk, J. Breitruck, A. Benner, S. Kreitmeier, K. Tobis, H. Dohner, and K. Dohner. 2002. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 100:4372-4380.
20. Fiedler, W., R. Mesters, H. Tinnefeld, S. Loges, P. Staib, U. Duhrsen, M. Flasshove, O.G. Ottmann, W. Jung, F. Cavalli, et al. 2003. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 102:2763-2767.
21. O'Farrell, A.M., J.M. Foran, W. Fiedler, H. Serve, R.L. Paquette, M.A. Cooper, H.A. Yuen, S.G. Louie, H. Kim, S. Nicholas, et al. 2003. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 9:5465-5476.
22. Smith, B.D., M. Levis, M. Beran, F. Giles, H. Kantarjian, K. Berg, K.M. Murphy, T. Dauses, J. Allebach, and D. Small. 2004. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 103:3669-3676.
23. Stone, R.M., J. De Angelo, I. Galinsky, E. Estey, V. Klimek, W. Grandin, D. Lebwohl, A. Yap, P. Cohen, E. Fox, et al. 2004. PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann. Hematol. 83:S89-S90.
24. Radomska, H.S., C.S. Huettner, P. Zhang, T. Cheng, D.T. Scadden, and D.G. Tenen. 1998. CCAAT/enhancer binding protein α is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol. Cell. Biol. 18:4301-4314.
25. Akashi, K., D. Traver, T. Miyamoto, and I.L. Weissman. 2000. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 404:193-197.
26. Zhang, D.-E., P. Zhang, N.D. Wang, C.J. Hetherington, G.J. Darlington, and D.G. Tenen. 1997. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice. Proc. Natl. Acad. Sci. USA. 94:569-574.
27. Wang, X., E.W. Scott, C.L. Sawyers, and A.D. Friedman. 1999. C/EBPα bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood. 94:560-571.
28. Ross, S.E., H.S. Radomska, B. Wu, P. Zhang, J.N. Winnay, L. Bajnok, W.S. Wright, F. Schaufele, D.G. Tenen, and O.A. MacDougald. 2004. Phosphorylation of C/EBPα inhibits granulopoiesis. Mol. Cell. Biol. 24:675-686.
29. Zhang, P., E.A. Nelson, H.S. Radomska, J. Iwasaki-Arai, K. Akashi, A.D. Friedman, and D.G. Tenen. 2002. Induction of granulocytic differentiation by two pathways. Blood. 99:4406-4412.
30. Pabst, T., B.U. Mueller, P. Zhang, H.S. Radomska, S. Narravula, S. Schnittger, G. Behre, W. Hiddemann, and D.G. Tenen. 2001. Dominant negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nat. Genet. 27:263-270.
31. Pabst, T., B.U. Mueller, N. Harakawa, D.-E. Zhang, and D.G. Tenen. 2001. AML1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia. Nat. Med. 7:444-451.
32. Perrotti, D., V. Cesi, R. Trotta, C. Guerzoni, G. Santilli, K. Campbell, A. Iervolino, F. Condorelli, C. Gambacorti-Passerini, M.A. Caligiuri, and B. Calabretta. 2001. BCR/ABL suppresses C/EBPα expression through inhibitory activity of hnRNP E 2. Nat. Genet. 30:48-58.
33. Helbling, D., B. Mueller, N.A. Timchenko, M.F. Fey, and T. Pabst. 2003. The myeloid transcription factor C/EBPα is a key target gene of the leukaemic fusion gene AML1/MDS1/EVI 1. Proc. Natl. Acad. Sci. USA. 101:13312-13317.
34. Westendorf, J.J., C.M. Yamamoto, N. Lenny, J.R. Downing, M.E. Selsted, and S.W. Hiebert. 1998. The t(8:21) fusion product, AML1-ETO, associates with C/EBP-α, inhibits C/EBP-α-dependent transcription, and blocks granulocytic differentiation. Mol. Cell. Biol. 18:322-333.
35. Gombart, A.F., W.K. Hofmann, S. Kawano, S. Takeuchi, U. Krug, S.W. Kwok, R.J. Larson, H. Asou, C.W. Miller, D. Hoelzer, and H.P. Koeffler. 2002. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein α in myelodysplastic syndromes and acute myeloid leukemias. Blood. 99:1332-1340.
36. Preudhomme, C., C. Sagot, N. Boissel, J.M. Cayuela, I. Tigaud, S. de Botton, X. Thomas, E. Rafffoux, C. Lamandin, S. Castaigne, et al. 2002. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 100:2717-2723.
37. Barjesteh van Waalwijk van Doorn-Khosrovani, S., C. Erpelinck, J. Meijer, S. van Oosterhoud, W.L. van Putten, P.J. Valk, H. Berna Beverloo, D.G. Tenen, B. Lowenberg, and R. Delwel. 2003. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol. J. 4:31-40.
38. Kaeferstein, A., U. Krug, J. Tiesmeier, M. Aivado, M. Faulhaber, M. Stadler, J. Krauter, U. Germing, W.K. Hofmann, H.P. Koeffler, et al. 2003. The emergence of a C/EBPα mutation in the clonal evolution of MDS towards secondary AML. Leukemia. 17:343-349.
39. Snaddon, J., M.L. Smith, M. Neat, M. Cambal-Parrales, A. Dixon-McIver, R. Arch, J.A. Amess, A.Z. Rohatiner, T.A. Lister, and J. Fitzgibbon. 2003. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M 2. Genes Chromosomes Cancer. 37:72-78.
40. Frohling, S., R.F. Schlenk, I. Stolze, J. Bihlmayr, A. Benner, S. Kreitmeier, K. Tobis, H. Dohner, and K. Dohner. 2004. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J. Clin. Oncol. 22:624-633.
41. Yokota, S., H. Kiyoi, M. Nakao, T. Iwai, S. Misawa, T. Okuda, Y. Sonoda, T. Abe, K. Kahsima, Y. Matsuo, and T. Naoe. 1997. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 11:1605-1609.
42. Lange, B., M. Valtieri, D. Santoli, D. Caracciolo, F. Mavilio, I. Gemperlein, C. Griffin, B. Emanuel, J. Finan, and P. Nowell. 1987. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood. 70:192-199.
43. Santoli, D., Y.C. Yang, S.C. Clark, B.L. Kreider, D. Caracciolo, and G. Rovera. 1987. Synergistic and antagonistic effects of recombinant human interleukin (IL) 3, IL-1 α, granulocyte and macrophage colony-stimulating factors (G-CSF and M-CSF) on the growth of GM-CSF-dependent leukemic cell lines. J. Immunol. 139:3348-3354.
44. Quentmeier, H., J. Reinhardt, M. Zaborski, and H.G. Drexler. 2003. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia. 17:120-124.
45. Ziegler-Heitbrock, H.W., E. Thiel, A. Futterer, V. Herzog, A. Wirtz, and G. Riethmuller. 1988. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int. J. Cancer. 41:456-461.
46. Spiekermann, K., R.J. Dirschinger, R. Schwab, K. Bagrintseva, F. Faber, C. Buske, S. Schnittger, L.M. Kelly, D.G. Gilliland, and W. Hiddemann. 2003. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT 3. Blood. 101:1494-1504.
47. Kelly, L.M., J.C. Yu, C.L. Boulton, M. Apatira, J. Li, C.M. Sullivan, I. Williams, S.M. Amaral, D.P. Curley, N. Duclos, et al. 2002. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 1:421-432.
48. Tse, K.F., E. Novelli, C.I. Civin, F.D. Bohmer, and D. Small. 2001. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia. 15:1001-1010.
49. Buchdunger, E., C.L. Cioffi, N. Law, D. Stover, S. Ohno-Jones, B.J. Druker, and N.B. Lydon. 2000. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295:139-145.
50. Johansen, L.M., A. Iwama, T.A. Lodie, K. Sasaki, D.W. Felsher, T.R. Golub, and D.G. Tenen. 2001. C-myc is a critical target for C/EBPα in granulopoiesis. Mol. Cell. Biol. 21:3789-3806.
51. D'Alo', F., L.M. Johansen, E.A. Nelson, H.S. Radomska, E.K. Evans, P. Zhang, C. Nerlov, and D.G. Tenen. 2003. The amino terminal and E2F interaction domains are critical for C/EBPα-mediated induction of granulopoietic development of hematopoietic cells. Blood. 102:3163-3171.
52. Sears, R., F. Nuckolls, E. Haura, Y. Taya, K. Tamai, and J.R. Nevins. 2000. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14:2501-2514.
53. Umek, R.M., A.D. Friedman, and S.L. McKnight. 1991. CCAAT-enhancer binding protein: a component of a differentiation switch. Science. 251:288-292.
54. Levis, M., K.F. Tse, B.D. Smith, E. Garrett, and D. Small. 2001. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood. 98:885-887.
55. Levis, M., J. Allebach, K.F. Tse, R. Zheng, B.R. Baldwin, B.D. Smith, S. Jones-Bolin, B. Ruggeri, C. Dionne, and D. Small. 2002. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 99:3885-3891.
56. Weisberg, E., C. Boulton, L.M. Kelly, P. Manley, D. Fabbro, T. Meyer, D.G. Gilliland, and J.D. Griffin. 2002. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 1:433-443.
57. Nishikawa, M., M. Yamamoto, Y. Watanabe, K. Kita, and H. Shiku. 2001. Clinical significance of low protein phosphatase-1 activity of blasts in acute myelogenous leukemia with high white cell counts. Int. J. Oncol. 18:559-565.
58. Franklin, C.C., and A.S. Kraft. 1995. Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells. Oncogene. 11:2365-2374.
59. Mizuki, M., J. Schwable, C. Steur, C. Choudhary, S. Agrawal, B. Sargin, B. Steffen, I. Matsumura, Y. Kanakura, F.D. Bohmer, et al. 2003. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood. 101:3164-3173.
60. Zheng, R., A.D. Friedman, M. Levis, L. Li, E.G. Weir, and D. Small. 2004. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression. Blood. 103:1883-1890.
61. Kelly, L.M., Q. Liu, J.L. Kutok, I.R. Williams, C.L. Boulton, and D.G. Gilliland. 2002. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 99:310-318.
62. Schwieger, M., J. Lohler, M. Fischer, U. Herwig, D.G. Tenen, and C. Stocking. 2004. A dominant-negative mutant of C/EBPα, associated with acute myeloid leukemias, inhibits differentiation of myeloid and erythroid progenitors of man but not mouse. Blood. 103:2744-2752.
63. Platanias, L.C. 2003. Map kinase signaling pathways and hematologic malignancies. Blood. 101:4667-4679.
64. Allen, L.F., J. Sebolt-Leopold, and M.B. Meyer. 2003. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol. 30:105-116.
65. Chang, F., L.S. Steelman, J.T. Lee, J.G. Shelton, P.M. Navolanic, W.L. Blalock, R.A. Franklin, and J.A. McCubrey. 2003. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 17:1263-1293.
66. Lunghi, P., A. Tabilio, P.P. Dall'Aglio, E. Ridolo, C. Carlo-Stella, P.G. Pelicci, and A. Bonati. 2003. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia. 17:1783-1793.
67. Matsuo, Y., R.A. MacLeod, C.C. Uphoff, H.G. Drexler, C. Nishizaki, Y. Katayama, G. Kimura, N. Fujii, E. Omoto, M. Harada, and K. Orita. 1997. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia. 11:1469-1477.
68. Steube, K.G., D. Teepe, C. Meyer, M. Zaborski, and H.G. Drexler. 1997. A model system in haematology and immunology: the human monocytic cell line MONO-MAC- 1. Leuk. Res. 21:327-335.
69. Whitmarsh, A.J., and R.J. Davis. 2001. Analyzing JNK and p38 mitogen-activated protein kinase activity. Methods Enzymol. 332:319-336.
70. Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T 4. Nature. 227:680-685.